Research collaboration aims to uncover new insights into ovarian biology and accelerate the development of personalized interventions in reproductive medicine…
ZOMACTON now approved for 5 pediatric and 1 adult indication Ferring will launch ZOMA-Jet® 10 Needle-Free Delivery System for…
New data show heat-stable carbetocin is as effective as oxytocin, the current standard of care, in preventing excessive bleeding…
Clinical trials demonstrated an average reduction of nighttime voids of 52% in women and 43% in men relative to mean…
Tuesday, June 5, 12:00-2:00 p.m., Dr. Lawrence Hookey to present “A Randomized, Assessor-Blinded, Multicenter Study Demonstrates the Efficacy and Safety…
rAd-IFN/Syn3, a novel gene therapy, is in Phase 3 development to treat high-grade non-muscle invasive bladder cancer patients, who…
• Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI)…
First and only FDA-Approved, Ready-to-Drink Low-Volume Bowel Prep Parsippany, NJ – February 12, 2018 – Ferring Pharmaceuticals Inc. announced today…
Ferring Expands U.S. Endocrinology Portfolio PARSIPPANY, N.J., January 31, 2018 – Ferring Pharmaceuticals Inc. today announced that the U.S. Food…
New Ready-to-Drink Low-Volume Colonoscopy Prep in a Premixed Liquid Solution Parsippany, NJ – November 29, 2017 – The U.S. Food…